Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

CA Cancer J Clin. 2010 May-Jun;60(3):194-201. doi: 10.3322/caac.20061. Epub 2010 Feb 2.

Authors

Glenn N Levine¹, Anthony V D'Amico, Peter Berger, Peter E Clark, Robert H Eckel, Nancy L Keating, Richard V Milani, Arthur I Sagalowsky, Matthew R Smith, Neil Zakai; American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association

Affiliation

¹ Michael E. DeBakey Veteran's Affairs Medical Center, Houston, TX, USA. glenn.levine@bcm.tmc.edu

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Androgen Antagonists / adverse effects*
Androgen Antagonists / therapeutic use
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Cardiovascular Diseases / chemically induced*
Cardiovascular Diseases / epidemiology
Cardiovascular Diseases / mortality
Humans
Male
Morbidity
Prostatic Neoplasms / drug therapy*
Risk Assessment
Risk Factors
United States / epidemiology

Substances

Androgen Antagonists
Antineoplastic Agents

Grants and funding